Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Up 423.2% in July

Posted by George Bondi on Aug 13th, 2026

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Get Free Report) was the target of a significant increase in short interest in the month of July. As of July 31st, there was short interest totaling 23,793 shares, an increase of 423.2% from the July 15th total of 4,548 shares. Based on an average daily trading volume, of 127,966 shares, the short-interest ratio is currently 0.2 days. Approximately 0.9% of the company’s shares are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cardio Diagnostics in a research note on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Cardio Diagnostics has a consensus rating of “Sell”.

Check Out Our Latest Research Report on Cardio Diagnostics

Cardio Diagnostics Stock Down 5.1%

Cardio Diagnostics stock traded down $0.11 during midday trading on Thursday, reaching $2.05. 164,305 shares of the stock traded hands, compared to its average volume of 1,653,457. The stock’s fifty day moving average is $1.86 and its 200-day moving average is $2.14. Cardio Diagnostics has a 12 month low of $0.97 and a 12 month high of $7.91. The stock has a market cap of $6.07 million, a P/E ratio of -0.70 and a beta of 2.27.

Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.51) earnings per share (EPS) for the quarter. The firm had revenue of $0.01 million during the quarter. Cardio Diagnostics had a negative return on equity of 80.78% and a negative net margin of 43,133.33%.

Hedge Funds Weigh In On Cardio Diagnostics

Large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new position in Cardio Diagnostics during the 1st quarter valued at about $30,000. Citadel Advisors LLC purchased a new stake in shares of Cardio Diagnostics during the third quarter worth about $79,000. Finally, DRW Securities LLC grew its stake in shares of Cardio Diagnostics by 122.8% during the fourth quarter. DRW Securities LLC now owns 40,463 shares of the company’s stock worth $110,000 after acquiring an additional 22,298 shares during the last quarter. 8.06% of the stock is currently owned by institutional investors.

Cardio Diagnostics Company Profile

(Get Free Report)

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.